Novo Nordisk A/S (NVO) Stake Raised by Equitable Trust Co.

Equitable Trust Co. increased its holdings in Novo Nordisk A/S (NYSE:NVO) by 11.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 6,359 shares of the company’s stock after purchasing an additional 663 shares during the period. Equitable Trust Co.’s holdings in Novo Nordisk A/S were worth $293,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in NVO. Roundview Capital LLC boosted its position in Novo Nordisk A/S by 1.3% during the 4th quarter. Roundview Capital LLC now owns 16,870 shares of the company’s stock valued at $777,000 after buying an additional 210 shares during the period. Garrison Financial Corp boosted its position in Novo Nordisk A/S by 2.5% during the 4th quarter. Garrison Financial Corp now owns 12,510 shares of the company’s stock valued at $576,000 after buying an additional 300 shares during the period. Edmond DE Rothschild Holding S.A. boosted its position in Novo Nordisk A/S by 2.4% during the 4th quarter. Edmond DE Rothschild Holding S.A. now owns 13,702 shares of the company’s stock valued at $632,000 after buying an additional 324 shares during the period. Advisor Partners LLC boosted its position in Novo Nordisk A/S by 2.7% during the 4th quarter. Advisor Partners LLC now owns 12,634 shares of the company’s stock valued at $582,000 after buying an additional 338 shares during the period. Finally, Dorsey & Whitney Trust CO LLC boosted its position in Novo Nordisk A/S by 6.7% during the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 6,727 shares of the company’s stock valued at $310,000 after buying an additional 420 shares during the period. 7.06% of the stock is owned by institutional investors.

NYSE:NVO traded down $0.12 on Friday, reaching $48.39. 1,127,664 shares of the stock traded hands, compared to its average volume of 1,358,723. The firm has a market cap of $118.24 billion, a P/E ratio of 19.20, a P/E/G ratio of 2.14 and a beta of 0.60. Novo Nordisk A/S has a 12 month low of $41.23 and a 12 month high of $52.83.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Friday, February 1st. The company reported $0.54 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.03). The company had revenue of $4.55 billion for the quarter, compared to analysts’ expectations of $4.36 billion. Novo Nordisk A/S had a net margin of 34.67% and a return on equity of 80.45%. Sell-side analysts anticipate that Novo Nordisk A/S will post 2.47 EPS for the current fiscal year.

Several equities research analysts have weighed in on the stock. Zacks Investment Research cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Wednesday, February 13th. Handelsbanken cut shares of Novo Nordisk A/S from a “buy” rating to an “accumulate” rating and set a $48.61 price target for the company. in a research report on Monday, February 4th. BNP Paribas assumed coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 29th. They set an “outperform” rating for the company. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research report on Friday, February 1st. They set an “equal weight” rating for the company. Finally, Barclays restated a “sell” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 5th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the stock. Novo Nordisk A/S presently has an average rating of “Hold” and a consensus target price of $52.31.

TRADEMARK VIOLATION WARNING: “Novo Nordisk A/S (NVO) Stake Raised by Equitable Trust Co.” was originally published by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.baseballdailydigest.com/news/2019/04/21/equitable-trust-co-grows-position-in-novo-nordisk-a-s-nvo.html.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Further Reading: How is diluted EPS different from basic EPS?

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.